CompletedNCT04236921Updated Jan 22, 2020

Bioequivalence Bewteen DopaSnap® (Cabidopa/Levopdoap 25/100 mg Tablet) and Carbidopa/Levodopa 25/100 mg Tablet (Actavis)

A Phase 1 interventional study of DopaSnap® and RDL of CD-LD in Other, sponsored by Riverside Pharmacueticals Corporation. Completed at 1 site in Canada. Open to participants aged 35 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-22.

Sponsored by Riverside Pharmacueticals Corporation · Phase 1, Interventional, and Basic science

From the registry’s dates

Primary completion was Sep 2019, 7 years ago, and no results have been posted to the registry.
Registered 4 months after the study started (first participant enrolled Jul 2019, registered Dec 2019).

Phase: Phase 1
Study type: Interventional
Enrollment: 57
Allocation: Randomized
Ages: 35 Years to 75 Years
Sex: All

Study summary

This will be a single center, bioequivalence and food-effect, open-label study designed to be conducted in three sequential parts:

Read the detailed description

This will be a single center, bioequivalence and food-effect, open-label study designed to be conducted in three sequential parts:

Part I: bioequivalence, food-effect, randomized, open-label, single dose, 3-period, 6-sequence, crossover design.
Part II: multiple-dose (every 4 hours), open-label, 1-period design.
Part III: multiple-dose (every 2 hours), open-label, 1-period design.

Conditions studied

Other

In context

Lead sponsor

This is the only study on the registry with Riverside Pharmacueticals Corporation as lead sponsor.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 35 Years to 75 Years
Sexes eligible: All
Accepts healthy volunteers: Yes

Inclusion criteria

Male or female, non-smoker (no use of tobacco or nicotine products within 3 months prior to screening), ≥35 and ≤75 years of age, with BMI > 18.5 and \< 30.0 kg/m2 and body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females.
Healthy as defined by:
1. the absence of clinically significant illness and surgery within 4 weeks prior to dosing. Subjects vomiting within 24 hours pre-dose will be carefully evaluated for upcoming illness/disease. Inclusion pre-dosing is at the discretion of the Qualified Investigator.
2. the absence of clinically significant history of neurological, endocrinal, cardiovascular, pulmonary, hematological, immunologic, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease.
Females of childbearing potential who are sexually active with a male partner must be willing to use one of the following acceptable contraceptive methods throughout the study and for 30 days after the last study drug administration:
1. intra-uterine contraceptive device placed at least 4 weeks prior to study drug administration;
2. male condom with intravaginally applied spermicide starting at least 21 days prior to study drug administration;
3. hormonal contraceptives starting at least 4 weeks prior to study drug administration and must agree to use the same hormonal contraceptive throughout the study;
4. sterile male partner (vasectomized since at least 6 months).
Capable of consent.

Exclusion criteria

Exclusion Criteria:

1. Any clinically significant abnormality at physical examination, clinically significant abnormal laboratory test results or positive test for hepatitis B, hepatitis C, or HIV found during medical screening.
  1. Positive urine drug screen, alcohol breath test, or urine cotinine test at screening.
  1. History of allergic reactions to carbidopa, levodopa, or other related drugs, or to any excipient in the formulation.
  1. Positive pregnancy test at screening. 5) Clinically significant ECG abnormalities or vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.
  1. History of significant alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to the screening visit (more than 14 units of alcohol per week [1 unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]).
  1. History of significant drug abuse within 1 year prior to screening or use of soft drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and amphetamine derivatives) within 1 year prior to screening.
  1. Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days prior to the first dosing, administration of a biological product in the context of a clinical research study within 90 days prior to the first dosing, or concomitant participation in an investigational study involving no drug or device administration.
  1. Use of medication other than topical drug products without significant systemic absorption and hormonal contraceptives:
  2. prescription medication within 14 days prior to the first dosing;
  3. over-the-counter products and natural health products (including herbal remedies, homeopathic and traditional medicines, probiotics, food supplements such as vitamins, minerals, amino acids, essential fatty acids, and protein supplements used in sports) within 14 days prior to the first dosing, with the exception of the occasional use of acetaminophen (up to 2 g daily);
  4. a depot injection or an implant of any drug within 3 months prior to the first dosing (other than hormonal contraceptives);
  5. MAO inhibitors within 30 days prior to the first dosing; 10) Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at screening) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the first dosing.
    1. Hemoglobin \< 128 g/L (males) and \< 115 g/L (females) and hematocrit \< 0.36 L/L (males) and \< 0.32 L/L (females) at screening.
    1. Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.
    1. Breast-feeding subject. 14) History or presence of myasthenia gravis. 15) Treatment with centrally active drugs or those affecting peripheral cholinergic transmission within 3 months of screening.
    1. The presence of history of narrow angle glaucoma. 17) The presence of history of depression, suicidal tendencies, and other psychotic disorders.
    1. The presence of history of myocardial infarction, arrhythmias, bronchial asthma and other cardiovascular, or pulmonary disease.
    1. The presence of history of melanoma and suspicious undiagnosed skin lesions.
    1. The presence of history of neuroleptic malignant syndrome and non-traumatic rhabdomyolysis.
    1. The presence of history of peptic ulcer disease or undiagnosed recurrent gastro-intestinal bleeding.
    1. The presence of history of convulsions. 23) HAMD-7 score above 3 at screening.

Study design

Phase: Phase 1
Primary purpose: Basic science
Allocation: Randomized
Intervention model: Crossover assignment
Masking: None (open label)
Enrollment: 57 participants (actual)

Study arms

Experimental
Treatment A
1 x DopaSnap® tablet, administered under fasting conditions.
Drug: DopaSnap®
Active comparator
Treatment B
1 x RLD of CD-LD tablet administered under fasting conditions.
Drug: RDL of CD-LD
Experimental
Treatment C
Test - fed 1 x DopaSnap® tablet , administered under fed conditions.
Drug: DopaSnap®
Experimental
Treatment D
DopaSnap® tablet administered at 0 and 4 hours post-first dose, for a total daily dose of CD/LD 50/200 mg.
Drug: DopaSnap®
Experimental
Treatment E
½ x DopaSnap® tablet administered at 0, 2, 4, and 6 hours post-first dose
Drug: DopaSnap®

Interventions

DrugDopaSnap®
immediate release CD/LD 25/100mg; Riverside Pharmaceuticals Corporation, USA
Also known as: test product
DrugRDL of CD-LD
(immediate release CD/LD 25/100mg; Merck Sharp \& Dohme Corp., USA),
Also known as: Reference

What researchers measure

Primary outcomes

compare the rate and extent of absorption
• to compare the rate and extent of absorption of the immediate-release CD/LD 25/100 mg DopaSnap® tablet (Test) versus the immediate-release CD-LD tablet (Reference), each administered orally as a single tablet under fasting conditions. AUC0-t
Time frame: pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, and 24 hours post-dose.
compare the rate and extent of absorption
• to compare the rate and extent of absorption of the immediate-release CD/LD 25/100 mg DopaSnap® tablet (Test) versus the immediate-release CD-LD tablet (Reference), each administered orally as a single tablet under fasting conditions. AUC0-inf
Time frame: pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, and 24 hours post-dose.
compare the rate and extent of absorption
• to compare the rate and extent of absorption of the immediate-release CD/LD 25/100 mg DopaSnap® tablet (Test) versus the immediate-release CD-LD tablet (Reference), each administered orally as a single tablet under fasting conditions. Cmax
Time frame: pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, and 24 hours post-dose.
compare the rate and extent of absorption
• to compare the rate and extent of absorption of the immediate-release CD/LD 25/100 mg DopaSnap® tablet (Test) versus the immediate-release CD-LD tablet (Reference), each administered orally as a single tablet under fasting conditions. Residual area
Time frame: pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, and 24 hours post-dose.
compare the rate and extent of absorption
• to compare the rate and extent of absorption of the immediate-release CD/LD 25/100 mg DopaSnap® tablet (Test) versus the immediate-release CD-LD tablet (Reference), each administered orally as a single tablet under fasting conditions. Tmax
Time frame: pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, and 24 hours post-dose.
compare the rate and extent of absorption
• to compare the rate and extent of absorption of the immediate-release CD/LD 25/100 mg DopaSnap® tablet (Test) versus the immediate-release CD-LD tablet (Reference), each administered orally as a single tablet under fasting conditions. T½ el
Time frame: pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, and 24 hours post-dose.
compare the rate and extent of absorption
• to compare the rate and extent of absorption of the immediate-release CD/LD 25/100 mg DopaSnap® tablet (Test) versus the immediate-release CD-LD tablet (Reference), each administered orally as a single tablet under fasting conditions. Kel
Time frame: pre-dose and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, and 24 hours post-dose.
Effect of food on the pharmacokinetics (PK)
PK Parameters: AUC0-t
Time frame: A total of 25 blood samples will be collected: pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, and 12 hours post-first dose.
Effect of food on the pharmacokinetics (PK)
PK Parameters: Cmax
Time frame: A total of 25 blood samples will be collected: pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, and 12 hours post-first dose.
Effect of food on the pharmacokinetics (PK)
PK Parameters: Tmax
Time frame: A total of 25 blood samples will be collected: pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, and 12 hours post-first dose.

Secondary outcomes

PK profile of a fraction of the DopaSnap® tablet
• the PK profile of a fraction of the DopaSnap® tablet when administered at frequent intervals every 2 hours comparing to whole tablet every 4 hours PK Parameters: AUC0-t
Time frame: A total of 25 blood samples will be collected: pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, and 12 hours post-first dose.
PK profile of a fraction of the DopaSnap® tablet
• the PK profile of a fraction of the DopaSnap® tablet when administered at frequent intervals every 2 hours comparing to whole tablet every 4 hours PK Parameters: Tmax
Time frame: A total of 25 blood samples will be collected: pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, and 12 hours post-first dose.
PK profile of a fraction of the DopaSnap® tablet
• the PK profile of a fraction of the DopaSnap® tablet when administered at frequent intervals every 2 hours comparing to whole tablet every 4 hours PK Parameters: Cmax
Time frame: A total of 25 blood samples will be collected: pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, and 12 hours post-first dose.

Study locations

1 site

Syneous Health
Québec, Montreal H3x 2H9, Canada

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Jan 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT04236921
Lead sponsor: Riverside Pharmacueticals Corporation
Responsible party: Sponsor
First posted: Jan 22, 2020
Start date: Jul 15, 2019
Primary completion: Sep 11, 2019
Completion: Dec 1, 2019
Last update: Jan 22, 2020

Study contacts

Stephane Lamouche, PhD

principal investigator · Syneos Health

Oversight

Data monitoring committee: No
FDA-regulated drug: Yes
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion